Purchase Order 75N91018P00462

<p>The National Cancer Institute awarded a purchase order to Nexome Genomics Inc. for $10,000.00 on July 2, 2018. Performance occurs in Bethesda, Maryland. The order is firm fixed price with no small business set-aside. Work is scheduled for completion by August 2, 2018.</p>

<p>The National Cancer Institute issued a purchase order to Nexome Genomics Inc. for $12,250 on August 7, 2018. Work is performed in Bethesda, Maryland. The order is firm fixed price with an ultimate completion date of September 7, 2018. No small business set-aside applies.</p>

<p>The National Cancer Institute awarded a purchase order to Nexome Genomics Inc. valued at $14,075.00 on November 30, 2018. Performance occurs in Bethesda, Maryland. The order is firm fixed price with an ultimate completion date of December 30, 2018.</p>

<p>The National Cancer Institute awarded a purchase order to 10X Genomics, Inc. valued at $21,581.00 on August 28, 2018, with completion scheduled for September 28, 2018. Performance occurs at Bethesda, Maryland. The order is firm fixed price with no small business set-aside.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $24,158.08 on October 19, 2017, with an ultimate completion date of November 19, 2018. Performance occurs at Bethesda, Maryland. The order is firm fixed price with no set-aside designation. Specific requirements are not detailed in the source material.</p>

<p>The National Cancer Institute issued a purchase order to 10X Genomics, Inc. valued at $12,500 on May 30, 2018, with ultimate completion by June 4, 2019. Work is performed in Bethesda, Maryland. The order covers genomic analysis instruments, consumables, or bioinformatics software under firm fixed price terms with no set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Nexome Genomics Inc. for customized FISH probe panels, valued at $16,800.00, on December 9, 2019. Performance is located in Bethesda, Maryland. The order carries firm fixed price terms and an ultimate completion date of January 9, 2020.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $16,085.00 on May 17, 2019, with ultimate completion on June 14, 2020. Performance occurs in Bethesda, Maryland. The order is a firm fixed price service agreement with no set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $3,978.82 on April 25, 2017, with ultimate completion on September 18, 2017. Work is performed at Bethesda, Maryland. The order is priced on a firm fixed price basis. No set-aside was used.</p>

<p>The National Cancer Institute issued a $13,043.75 delivery order to Illumina, Inc. on August 29, 2018, for genomic analysis equipment and reagents.</p> <p>Place of performance is Bethesda, MD. The order has a firm fixed-price structure with an ultimate completion date of September 29, 2018. No set-aside was used.</p>